{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.0","value":"47.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"Cycle 1 Day 1: ADC"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.7","value":"93.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Cycle 1 Day 1: TAb"}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"}],"paramType":"MEAN","populationDescription":"The PK population included enrolled participants with sufficient dosing and PK data to reliably estimate PK parameters as determined by a clinical pharmacologist. The iPK population was the subset of PK population. The iPK population where data at specified timepoints was available.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose","title":"A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb","type":"SECONDARY","unitOfMeasure":"day*microgram per milliliter (day*ug/mL)"}